NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its third quarter net loss narrowed year over year as it continues to advance the development of its flagship liquid biopsy test toward commercialization.

For the three months ended Sept. 30, the Alameda, California-based diagnostic developer incurred a net loss of $3.0 million, or $.07 per share, compared to a loss of $6.9 million, or $.22 per share, in the year-ago period.

OncoCyte did not report any Q3 revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.

In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.

CNBC reports that half of academic researchers leave after about five years.

Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.